Is the genomic translational pipeline being disrupted?

The translational pipeline for genomic medicine has been well defined. However, as with any rapidly changing technology, innovations are difficult to predict leading to the potential to disrupt anticipated translation. Examples of potential disruptors such as laboratory-developed tests, direct-to-consumer testing, and patient-centered research are presented. Awareness of the disruptive nature of innovative approaches is necessary if these innovations are to be incorporated into current practice.